TP53 and breast cancer: Previous meta-analyses (Dunning et al., 1999; Hu et al., 2010a; Hu et al., 2010b; He et al., 2011; Sagne et al., 2013; Wu et al., 2013; Diakite et al., 2020a) had only reported TP53 IVS3 16 bp polymorphism with an increased BC risk in overall analysis and only one study (Wu et al., 2013) performed the analyses stratified by ethnicity.